Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT

Catherine G. Derington, Tyler H. Gums, Adam P. Bress, Jennifer S. Herrick, Tom H. Greene, Andrew E. Moran, William S. Weintraub, Ian M. Kronish, Donald E. Morisky, Katy E. Trinkley, Joseph J. Saseen, Kristi Reynolds, Jeffrey T. Bates, Dan R. Berlowitz, Tara I. Chang, Michel Chonchol, William C. Cushman, Capri G. Foy, Charles T. Herring, Lois Anne KatzMarie Krousel-Wood, Nicholas M. Pajewski, Leonardo Tamariz, Jordan B. King

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Total medication burden (antihypertensive and nonantihypertensive medications) may be associated with poor systolic blood pressure (SBP) control. We investigated the association of baseline medication burden and clinical outcomes and whether the effect of the SBP intervention varied according to baseline medication burden in SPRINT (Systolic Blood Pressure Intervention Trial). Participants were randomized to intensive or standard SBP goal (below 120 or 140 mm Hg, respectively); n=3769 participants with high baseline medication burden (≥5 medications) and n=5592 with low burden (<5 medications). Primary outcome: differences in SBP. Secondary outcomes: 8-item Morisky Medication Adherence Scale and modified Treatment Satisfaction Questionnaire for Medications measured at baseline and 12 months and incident cardiovascular disease events and serious adverse events throughout the trial. Participants in the intensive group with high versus low medication burden were less likely to achieve their SBP goal at 12 months (risk ratio, 0.91; 95% CI, 0.85-0.97) but not in the standard group (risk ratio, 0.98; 95% CI, 0.93-1.03; Pinteraction<0.001). High medication burden was associated with increased cardiovascular disease events (hazard ratio, 1.39; 95% CI, 1.14-1.70) and serious adverse events (hazard ratio, 1.34; 95% CI, 1.24-1.45), but the effect of intensive versus standard treatment did not vary between medication burden groups (Pinteraction>0.5). Medication burden had minimal association with adherence or satisfaction. High baseline medication burden was associated with worse intensive SBP control and higher rates of cardiovascular disease events and serious adverse events. The relative benefits and risks of intensive SBP goals were similar regardless of medication burden.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalHypertension
Volume74
Issue number2
DOIs
StatePublished - Aug 1 2019
Externally publishedYes

Fingerprint

Blood Pressure
Antihypertensive Agents
Cardiovascular Diseases

Keywords

  • blood pressure
  • cardiovascular diseases
  • hypertension
  • medication adherence
  • risk

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes : A Secondary Analysis of SPRINT. / Derington, Catherine G.; Gums, Tyler H.; Bress, Adam P.; Herrick, Jennifer S.; Greene, Tom H.; Moran, Andrew E.; Weintraub, William S.; Kronish, Ian M.; Morisky, Donald E.; Trinkley, Katy E.; Saseen, Joseph J.; Reynolds, Kristi; Bates, Jeffrey T.; Berlowitz, Dan R.; Chang, Tara I.; Chonchol, Michel; Cushman, William C.; Foy, Capri G.; Herring, Charles T.; Katz, Lois Anne; Krousel-Wood, Marie; Pajewski, Nicholas M.; Tamariz, Leonardo; King, Jordan B.

In: Hypertension, Vol. 74, No. 2, 01.08.2019, p. 267-275.

Research output: Contribution to journalArticle

Derington, CG, Gums, TH, Bress, AP, Herrick, JS, Greene, TH, Moran, AE, Weintraub, WS, Kronish, IM, Morisky, DE, Trinkley, KE, Saseen, JJ, Reynolds, K, Bates, JT, Berlowitz, DR, Chang, TI, Chonchol, M, Cushman, WC, Foy, CG, Herring, CT, Katz, LA, Krousel-Wood, M, Pajewski, NM, Tamariz, L & King, JB 2019, 'Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT', Hypertension, vol. 74, no. 2, pp. 267-275. https://doi.org/10.1161/HYPERTENSIONAHA.119.12907
Derington, Catherine G. ; Gums, Tyler H. ; Bress, Adam P. ; Herrick, Jennifer S. ; Greene, Tom H. ; Moran, Andrew E. ; Weintraub, William S. ; Kronish, Ian M. ; Morisky, Donald E. ; Trinkley, Katy E. ; Saseen, Joseph J. ; Reynolds, Kristi ; Bates, Jeffrey T. ; Berlowitz, Dan R. ; Chang, Tara I. ; Chonchol, Michel ; Cushman, William C. ; Foy, Capri G. ; Herring, Charles T. ; Katz, Lois Anne ; Krousel-Wood, Marie ; Pajewski, Nicholas M. ; Tamariz, Leonardo ; King, Jordan B. / Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes : A Secondary Analysis of SPRINT. In: Hypertension. 2019 ; Vol. 74, No. 2. pp. 267-275.
@article{1b0d9f84c8484e1fb09831b36f834d76,
title = "Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT",
abstract = "Total medication burden (antihypertensive and nonantihypertensive medications) may be associated with poor systolic blood pressure (SBP) control. We investigated the association of baseline medication burden and clinical outcomes and whether the effect of the SBP intervention varied according to baseline medication burden in SPRINT (Systolic Blood Pressure Intervention Trial). Participants were randomized to intensive or standard SBP goal (below 120 or 140 mm Hg, respectively); n=3769 participants with high baseline medication burden (≥5 medications) and n=5592 with low burden (<5 medications). Primary outcome: differences in SBP. Secondary outcomes: 8-item Morisky Medication Adherence Scale and modified Treatment Satisfaction Questionnaire for Medications measured at baseline and 12 months and incident cardiovascular disease events and serious adverse events throughout the trial. Participants in the intensive group with high versus low medication burden were less likely to achieve their SBP goal at 12 months (risk ratio, 0.91; 95{\%} CI, 0.85-0.97) but not in the standard group (risk ratio, 0.98; 95{\%} CI, 0.93-1.03; Pinteraction<0.001). High medication burden was associated with increased cardiovascular disease events (hazard ratio, 1.39; 95{\%} CI, 1.14-1.70) and serious adverse events (hazard ratio, 1.34; 95{\%} CI, 1.24-1.45), but the effect of intensive versus standard treatment did not vary between medication burden groups (Pinteraction>0.5). Medication burden had minimal association with adherence or satisfaction. High baseline medication burden was associated with worse intensive SBP control and higher rates of cardiovascular disease events and serious adverse events. The relative benefits and risks of intensive SBP goals were similar regardless of medication burden.",
keywords = "blood pressure, cardiovascular diseases, hypertension, medication adherence, risk",
author = "Derington, {Catherine G.} and Gums, {Tyler H.} and Bress, {Adam P.} and Herrick, {Jennifer S.} and Greene, {Tom H.} and Moran, {Andrew E.} and Weintraub, {William S.} and Kronish, {Ian M.} and Morisky, {Donald E.} and Trinkley, {Katy E.} and Saseen, {Joseph J.} and Kristi Reynolds and Bates, {Jeffrey T.} and Berlowitz, {Dan R.} and Chang, {Tara I.} and Michel Chonchol and Cushman, {William C.} and Foy, {Capri G.} and Herring, {Charles T.} and Katz, {Lois Anne} and Marie Krousel-Wood and Pajewski, {Nicholas M.} and Leonardo Tamariz and King, {Jordan B.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.119.12907",
language = "English (US)",
volume = "74",
pages = "267--275",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Association of Total Medication Burden with Intensive and Standard Blood Pressure Control and Clinical Outcomes

T2 - A Secondary Analysis of SPRINT

AU - Derington, Catherine G.

AU - Gums, Tyler H.

AU - Bress, Adam P.

AU - Herrick, Jennifer S.

AU - Greene, Tom H.

AU - Moran, Andrew E.

AU - Weintraub, William S.

AU - Kronish, Ian M.

AU - Morisky, Donald E.

AU - Trinkley, Katy E.

AU - Saseen, Joseph J.

AU - Reynolds, Kristi

AU - Bates, Jeffrey T.

AU - Berlowitz, Dan R.

AU - Chang, Tara I.

AU - Chonchol, Michel

AU - Cushman, William C.

AU - Foy, Capri G.

AU - Herring, Charles T.

AU - Katz, Lois Anne

AU - Krousel-Wood, Marie

AU - Pajewski, Nicholas M.

AU - Tamariz, Leonardo

AU - King, Jordan B.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Total medication burden (antihypertensive and nonantihypertensive medications) may be associated with poor systolic blood pressure (SBP) control. We investigated the association of baseline medication burden and clinical outcomes and whether the effect of the SBP intervention varied according to baseline medication burden in SPRINT (Systolic Blood Pressure Intervention Trial). Participants were randomized to intensive or standard SBP goal (below 120 or 140 mm Hg, respectively); n=3769 participants with high baseline medication burden (≥5 medications) and n=5592 with low burden (<5 medications). Primary outcome: differences in SBP. Secondary outcomes: 8-item Morisky Medication Adherence Scale and modified Treatment Satisfaction Questionnaire for Medications measured at baseline and 12 months and incident cardiovascular disease events and serious adverse events throughout the trial. Participants in the intensive group with high versus low medication burden were less likely to achieve their SBP goal at 12 months (risk ratio, 0.91; 95% CI, 0.85-0.97) but not in the standard group (risk ratio, 0.98; 95% CI, 0.93-1.03; Pinteraction<0.001). High medication burden was associated with increased cardiovascular disease events (hazard ratio, 1.39; 95% CI, 1.14-1.70) and serious adverse events (hazard ratio, 1.34; 95% CI, 1.24-1.45), but the effect of intensive versus standard treatment did not vary between medication burden groups (Pinteraction>0.5). Medication burden had minimal association with adherence or satisfaction. High baseline medication burden was associated with worse intensive SBP control and higher rates of cardiovascular disease events and serious adverse events. The relative benefits and risks of intensive SBP goals were similar regardless of medication burden.

AB - Total medication burden (antihypertensive and nonantihypertensive medications) may be associated with poor systolic blood pressure (SBP) control. We investigated the association of baseline medication burden and clinical outcomes and whether the effect of the SBP intervention varied according to baseline medication burden in SPRINT (Systolic Blood Pressure Intervention Trial). Participants were randomized to intensive or standard SBP goal (below 120 or 140 mm Hg, respectively); n=3769 participants with high baseline medication burden (≥5 medications) and n=5592 with low burden (<5 medications). Primary outcome: differences in SBP. Secondary outcomes: 8-item Morisky Medication Adherence Scale and modified Treatment Satisfaction Questionnaire for Medications measured at baseline and 12 months and incident cardiovascular disease events and serious adverse events throughout the trial. Participants in the intensive group with high versus low medication burden were less likely to achieve their SBP goal at 12 months (risk ratio, 0.91; 95% CI, 0.85-0.97) but not in the standard group (risk ratio, 0.98; 95% CI, 0.93-1.03; Pinteraction<0.001). High medication burden was associated with increased cardiovascular disease events (hazard ratio, 1.39; 95% CI, 1.14-1.70) and serious adverse events (hazard ratio, 1.34; 95% CI, 1.24-1.45), but the effect of intensive versus standard treatment did not vary between medication burden groups (Pinteraction>0.5). Medication burden had minimal association with adherence or satisfaction. High baseline medication burden was associated with worse intensive SBP control and higher rates of cardiovascular disease events and serious adverse events. The relative benefits and risks of intensive SBP goals were similar regardless of medication burden.

KW - blood pressure

KW - cardiovascular diseases

KW - hypertension

KW - medication adherence

KW - risk

UR - http://www.scopus.com/inward/record.url?scp=85073670566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073670566&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.119.12907

DO - 10.1161/HYPERTENSIONAHA.119.12907

M3 - Article

C2 - 31256717

AN - SCOPUS:85073670566

VL - 74

SP - 267

EP - 275

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -